Norland gets clearance for Apollo

Article

Ultrasound-based bone densitometers may be attracting the most attention in the market, but investment continues in traditional dual-energy x-ray absorptiometry (DEXA) systems. One company that follows this philosophy is White Plains, NY-based Norland

Ultrasound-based bone densitometers may be attracting the most attention in the market, but investment continues in traditional dual-energy x-ray absorptiometry (DEXA) systems. One company that follows this philosophy is White Plains, NY-based Norland Medical Systems, which has received Food and Drug Administration 510(k) clearance for its low-cost Apollo DXA.

Apollo DXA is a heel-scanning system that will sell for less than $20,000. It features a scan time of under 15 seconds and can be operated from a hand-held control console. A laptop computer and a black-and-white inkjet printer are available as options with Apollo DXA.

Norland officially introduced Apollo DXA at the American College of Obstetricians and Gynecologists meeting last month in New Orleans, where the company also demonstrated its Paris ultrasound-based densitometer. Sales of Paris are already under way outside the U.S., and the company expects to receive FDA approval of its premarket approval application by the fall.

In other company news, Norland's financial results continue to reflect the uncertainty in the U.S. bone densitometry market (SCAN 4/1/98). In its first quarter (end-March), Norland's revenues dipped 52.4% to $2.1 million, compared with $4.3 million reported in the same period last year. The company posted a net loss of $1.9 million, compared with net income of $104,000 in 1997.

Norland is seeing an improvement in second-quarter product sales, however, and also believes that a recently announced deal with Tokai Financial Services will help spur stronger financial results. Tokai, based in Berwyn, PA, will provide product financing for U.S. purchasers of Norland's x-ray bone densitometers.

Recent Videos
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
Related Content
© 2025 MJH Life Sciences

All rights reserved.